摘要
目的探讨阿奇霉素与红霉素治疗小儿支原体肺炎的临床疗效及安全性。方法选取2012年12月至2014年12月我院收治的支原体肺炎患儿80例作为研究对象,随机分为A组和H组,每组40例。A组患儿采用阿奇霉素进行治疗,H组患儿采用红霉素进行治疗,比较两组患儿临床疗效、不良反应发生率、住院天数和临床症状消失时间。结果 A组患儿治疗总有效率为92.5%,高于H组的65.0%,差异显著(P<0.05);A组不良反应发生率为10.0%,低于H组的25.0%,差异有统计学(P<0.05);A组住院天数和临床症状消失时间短于H组(P<0.05)。结论采用阿奇霉素治疗小儿支原体肺炎患者具有较好的疗效,可提高总有效率,降低不良反应发生率,安全性高,值得临床推广。
Objective To compare the clinical efficacy and safety between azithromycin and erythromycin in the treatment of children mycoplasma pneumonia. Methods Eighty cases of children with mycoplasma pneumonia were selected from December 2012 to December 2014 in our hospital and randomly divided into group A and group H, with 40 cases in each group. Group A was treated with azithromycin, and group H was treated with erythromycin. The clinical efficacy, adverse reaction rates, length of hospital stay and time of clinical symptoms of the two groups were compared. Results The total efficiency rate of group A was 92.5%, which was significantly higher than 65.0% of the group H （P〈0.05）. The incidence rate of adverse reactions of group A was 10.0%, lower than 25.0% of the group H （P〈0.05）. The hospital and clinical symptoms of group A were shorter than those of the group H （P〈0.05）. Conclusion Azithromycin has better efficacy in the treatment of children mycoplasma pneumonia, it can improve the total efficiency rate and reduce the incidence rate of adverse reactions and with high safety, which is worthy of clinical application
出处
《临床医学研究与实践》
2017年第12期113-114,共2页
Clinical Research and Practice
关键词
阿奇霉素
红霉素
小儿支原体肺炎
azithromycin
erythromycin
children mycoplasma pneumonia
